Healthcare Utilisation of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA): A European Perspective

Speaker(s)

Jakes R1, Kwon N2, Huynh L3, Hwee J4, Baylis L5, Alfonso-Cristancho R6, Du S7, Khanal A3, Duh MS3
1GSK, London, UK, 2GSK, Brentford, UK, 3Analysis Group, Inc., Boston, MA, USA, 4GSK, Mississauga, ON, Canada, 5GSK, Durham, NC, USA, 6GSK, Collegeville, PA, USA, 7Analysis Group, Inc., Union City, NJ, USA

Presentation Documents

OBJECTIVES: EGPA is a rare chronic disease characterised by the combination of vasculitis, hypereosinophilia and asthma. Manifestations can affect any organ system. Treatment relies heavily on systemic corticosteroids and immunosuppressants. Published literature on the burden of EGPA in Europe is limited. We described EGPA-related healthcare resource use (HCRU) using a large real-world cohort of patients in Europe with a confirmed diagnosis of EGPA.

METHODS: This retrospective chart review study included patients ≥12 years of age with a confirmed EGPA diagnosis and ≥1 year of follow-up data (first physician encounter: Jan 2015–Dec 2019). A panel of 204 physicians across 5 European countries (France, Germany, Italy, Spain, UK). HCRU was described by EGPA-related visits (outpatient, hospitalisations, emergency room [ER]) and hospital stay duration.

RESULTS: Charts of 407 patients were included; 80–85 patients per country. The median (IQR) age at EGPA diagnosis was 44.5 (32.8–53.7) years and 57% of patients were male. Overall, 85% of patients had outpatient visits, with a mean (SD) rate among all patients of 5.9 (38.0) visits per person per year (PPPY); this varied between counties from 3.8 (2.8) visits PPPY (UK) to 11.3 (78.7) visits PPPY (France). Overall, 37% of patients had hospitalisations (mean [SD] rate: 0.5 [1.3] PPPY) and 26% had ER visits (mean [SD] rate: 0.3 [1.0] PPPY). The proportion of patients with these visits varied between countries (hospitalisations: 24% [Germany] to 46% [Spain]; ER: 11% [Germany] to 61% [Spain]). The mean (SD) length of hospital stays also varied from 1.5 (3.0) days (Germany) to 5.1 (6.9) days (Spain), compared to 3.1 (5.7) days overall.

CONCLUSIONS: The HCRU burden for patients with EGPA in Europe was considerable. Patients had frequent outpatient visits and many required ER visits and hospitalisation. Regional variability suggests differences in EGPA-related healthcare delivery and disease control.

Funding: GSK [214661]

Code

EE607

Topic

Economic Evaluation

Disease

SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Gastrointestinal Disorders, SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c